Public Announcement
ASX Code: 1AI

Appointment of Pharmaceutical Executive Dr. Sarah Siggins to the Scientific Advisory Board

Highlights:

- Dr. Siggins is an experienced pharmaceutical executive with 8+ years at Johnson & Johnson Innovative Medicine and 5+ years at Bristol-Myers Squibb.
- Dr. Siggins to provide strategic advice over potential commercial partnerships in AI-generated and other drug targets owned by the Company.
- Appointment follows initial readout of 24 AI-generated drugs delivered by the AlgoraeOS AI-enabled drug discovery platform.
- Former Senior Director and Medical Affairs Lead at Johnson & Johnson Innovative Medicine, Asia Pacific Strategy.
- Successfully led medical strategies for multiple blockbuster therapies across the APAC region.

Melbourne, Australia – 28 November 2024: Algorae Pharmaceuticals ('Algorae' or 'the Company') (ASX: 1AI), an artificial-intelligence ('AI') enabled drug discovery and development company today announces the appointment of highly experienced pharmaceutical executive, Dr. Sarah Siggins to its Scientific Advisory Board.

Dr. Siggins brings an extraordinary breadth of expertise and leadership from her 14+ years in the pharmaceutical industry, including senior roles at globally recognised company Johnson & Johnson Innovative Medicine.

Dr. Siggins has led the development and execution of medical strategies across multiple therapeutic areas, including neuroscience, oncology, cardiopulmonary and immunology. Her career highlights include:

- Leading high-performing teams and fostering collaboration across regulatory, Research and Development ('R&D') and commercial divisions to deliver innovative patient-centric solutions.
- Spearheading pivotal clinical trials and early-access programs, ensuring access to life-saving therapies in complex and diverse markets.
- Launching critical therapies in hematology and oncology, including ground-breaking immuno-oncology agents.
- Spearheaded early-access programs and multi-country clinical trials, ensuring patient access to life-saving treatments.
- Published 15+ peer-reviewed articles and led groundbreaking research on hematopoietic stem cells.

In addition to her industry leadership, Dr. Siggins holds a PhD in Biosciences from the University of Helsinki, and has authored over 15 peer-reviewed publications. Her postdoctoral research in hematopoietic stem cells has earned her international recognition.

Chairman, David Hainsworth commented: *"Dr. Siggins' unparalleled experience in pharmaceutical innovation and strategic execution will be invaluable as we advance our pipeline of drug candidates. She brings a deep understanding of the APAC regulatory and commercialisation environment having held senior executive roles within large pharmaceutical companies, most recently Johnson & Johnson. Dr. Siggins' pharmaceutical and scientific expertise will position her as a key contributor to our Scientific Advisory Board and we are delighted to announce her appointment."*

Dr. Sarah Siggins said, *"I look forward to working with the Board and scientific team, to enable Algorae Pharmaceuticals achieve their ambition to advance the development of new technologies and innovative therapies in diseases of high unmet needs. This is an exciting time to be involved in such programs with a dedicated team as they lead the way to improve patient outcomes and quality of life".*

The Board warmly welcomes Dr. Siggins and looks forward to her contributions in guiding Algorae Pharmaceuticals through its next phase of growth and innovation. Dr. Siggins will officially commence her role on 1 January 2025.

This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.

End

For more information, please visit www.algoraepharma.com

Corporate and Media Enquiries
Mr Brad Dilkes - Director
P: +61 422 180 317
E: brad@algoraepharma.com

About Algorae Pharmaceuticals

Algorae is actively expanding its therapeutic pipeline using a proprietary artificial intelligence ('AI') drug discovery and development platform, known as Algorae Operating System ('AlgoraeOS'). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the aim of AlgoraeOS is to uncover synergistic fixed dose drug combinations that lead to the development of novel and effective treatments for any medical condition, aligning with Algorae's commitment to address unmet medical needs.

The Company has assembled a proficient R&D team and established collaborations with reputable academic institutions to advance its promising drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson's disease. Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.